Atopic Dermatitis Cream Market Report 2026

The atopic dermatitis cream market size has grown strongly in recent years. It will grow from $5.42 billion in 2025 to $5.89 billion in 2026 at a compound annual growth rate (CAGR) of 8.6%. The growth in the historic period can be attributed to increasing prevalence of atopic dermatitis across age groups, growing awareness of chronic eczema management, wider availability of topical corticosteroid therapies, rising dermatologist consultations, expansion of retail dermatology products.

The atopic dermatitis cream market size is expected to see strong growth in the next few years. It will grow to $8.11 billion in 2030 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to increasing development of targeted topical therapies, rising demand for personalized dermatology treatments, expansion of online pharmacy distribution, growing focus on long-term skin barrier restoration, increasing adoption of non-steroidal innovations. Major trends in the forecast period include increasing adoption of non-steroidal anti-inflammatory creams, rising demand for barrier repair and ceramide-based formulations, growing preference for steroid-sparing treatment options, expansion of pediatric-safe topical therapies, enhanced focus on long-term flare management.

The increasing prevalence of eczema is anticipated to fuel the expansion of the atopic dermatitis cream market in the future. Eczema is a skin disorder that leads to itching, redness, dryness, and swelling. Demand for eczema treatments is growing as more individuals face allergies and sensitive skin issues, boosting the need for reliable therapies and skincare products. Atopic dermatitis creams effectively treat eczema by easing inflammation, relieving itchiness, repairing the skin's protective barrier, and averting additional irritation or infections, which supports recovery and sustained skin wellness in impacted regions. For instance, in December 2024, the Royal Australian College of General Practitioners, an Australia-based research organization, indicated that around 16% of Australians suffer from eczema, with about 25% of those cases deemed severe. Thus, the growing incidence of eczema is propelling the atopic dermatitis cream market forward.

Major companies in the atopic dermatitis cream market are prioritizing the development of innovative steroid-free therapies, broadening patient access via insurance and support initiatives, and promoting sustained disease management through safer topical options. Steroid-free therapies serve as alternatives to corticosteroids, addressing inflammation and skin issues effectively while avoiding the risks associated with steroids. For example, in July 2024, Arcutis Biotherapeutics Inc., a U.S.-based biopharmaceutical firm, introduced ZORYVE (roflumilast) cream 0.15% in the U.S. for mild to moderate atopic dermatitis in adults and children aged six and older. This once-daily, steroid-free cream delivers rapid itch relief, enhances disease clearance, and enables long-term management without the typical side effects of conventional topical therapies. ZORYVE is available at pharmacies with instant coverage under certain pharmacy benefit managers (PBMs) contracts.

In October 2024, Organon & Co., a U.S.-based pharmaceutical firm, purchased Dermavant Sciences Ltd. for an undisclosed sum. This deal bolsters its dermatology lineup by incorporating VTAMA, a pioneering nonbiologic, non-steroidal topical treatment for plaque psoriasis that may soon gain approval for atopic dermatitis. Dermavant Sciences Ltd. is a U.S.-based pharmaceutical company focused on delivering treatments for dermatological disorders.

Major companies operating in the atopic dermatitis cream market are Pfizer Inc., AbbVie Inc., Bayer AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Viatris Inc, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Organon & Co., Galderma S.A., Incyte Corporation, Leo Pharma A/S, Almirall S.A., Boehringer Ingelheim, Arcutis Biotherapeutics Inc., Medimetriks Pharmaceuticals Inc.

North America was the largest region in the atopic dermatitis cream market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atopic dermatitis cream market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the atopic dermatitis cream market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the atopic dermatitis cream market by increasing costs of imported pharmaceutical excipients, active pharmaceutical ingredients, packaging materials, and specialized manufacturing inputs used in topical formulations. Manufacturers in North America and Europe are particularly affected due to reliance on globally sourced ingredients, while Asia-Pacific faces pricing pressures on export-oriented production. These tariffs are contributing to higher production costs and influencing pricing strategies across retail and hospital pharmacy channels. However, they are also encouraging regional sourcing, localized formulation manufacturing, and investment in domestic pharmaceutical production capabilities.

The atopic dermatitis cream market research report is one of a series of new reports that provides atopic dermatitis cream market statistics, including atopic dermatitis cream industry global market size, regional shares, competitors with a atopic dermatitis cream market share, detailed atopic dermatitis cream market segments, market trends and opportunities, and any further data you may need to thrive in the atopic dermatitis cream industry. This atopic dermatitis cream market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

An atopic dermatitis cream is a topical product, typically based on corticosteroids, emollients, or non-steroidal agents, crafted to ease inflammation, alleviate itching, and strengthen the skin barrier for those with chronic eczema. It achieves this by replenishing moisture, minimizing flare-ups, and improving everyday skin care comfort.

The primary categories of atopic dermatitis creams include corticosteroid creams, calcineurin inhibitor creams, PDE4 inhibitor creams, moisturizing creams, and additional types. Corticosteroid creams are topical treatments applied directly to the skin, which alleviate inflammation, redness, and itching by dampening immune activity in conditions like eczema. These products serve various age demographics, such as pediatric, adult, and geriatric patients, and are available via distribution channels including hospital pharmacies, retail pharmacies, online pharmacies, and more.

The atopic dermatitis cream market consists of sales of barrier repair creams, antihistamine-infused creams, ceramide-enriched creams, herbal and plant-based creams, and probiotic-infused creams. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.